- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01646671
Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients
A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Patients With Severe Hypertension
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Summaries for treatment-emergent adverse events, serious adverse events and death were provided by the following actual treatment regimen (actual treatment patients received) in addition to all patients: LCZ696 200mg, 400mg, 400mg+other hypertensive medications.
Summaries for others than above were provided by the following treatment regimen (determined by the maximal treatment patients received) in addition to all patients: LCZ696 200mg, 400mg, 400mg+other hypertensive medications.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
Kanagawa
-
Yokohama-city, Kanagawa, Giappone, 231-0023
- Novartis Investigative Site
-
-
Kyoto
-
Kyoto-city, Kyoto, Giappone, 606-8507
- Novartis Investigative Site
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Giappone, 113-0031
- Novartis Investigative Site
-
Hachioji-city, Tokyo, Giappone, 192-0918
- Novartis Investigative Site
-
Minato-ku, Tokyo, Giappone, 105-7390
- Novartis Investigative Site
-
Minato-ku, Tokyo, Giappone, 108-0075
- Novartis Investigative Site
-
Ota-ku, Tokyo, Giappone, 143-0023
- Novartis Investigative Site
-
Shibuya-ku, Tokyo, Giappone, 150-0002
- Novartis Investigative Site
-
Shinagawa-ku, Tokyo, Giappone, 141-0032
- Novartis Investigative Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Satisfy office msSBP ≥180 mmHg or office msDBP ≥110 mmHg at baseline
Exclusion Criteria:
- Patients show msSBP ≥220 mmHg and/or msDBP ≥120 mmHg
- History of angioedema, drug-related or otherwise, as reported by the patient
- Patients unwilling or not able to discontinue safely the use of current antihypertensive medications during the study, as required by the protocol.
- Patients have significant cardiovascular co-morbidities
- Patients who previously entered a LCZ696 study and had been randomized or enrolled into the active drug treatment epoch.
Other protocol defined inclusion/exclusion criteria may apply.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: LCZ696 200 mg
All participants were started on LCZ696 200 mg once daily on day 1.
Participants who achieved mean sitting diastolic blood pressure (msDBP) of < 100 mmHg and mean sitting systolic blood pressure (msSBP) of < 160 mmHg at week 2 or a msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4 and for the duration of the study continued at 200 mg LCZ696 once daily.
|
LCZ696 200 mg tablet once daily
2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily
2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily plus other HTN medications
|
Sperimentale: LCZ696 400 mg
All participants were started on LCZ696 200 mg once daily on day 1.
For participants who did not achieve mean sitting diastolic blood pressure (msDBP) of < 100 mmHg and mean sitting systolic blood pressure (msSBP) of < 160 mmHg at week 2 or a msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4, and did not have any signs of safety concerns, the LCZ696 dose was increased to 400 mg once daily.
|
LCZ696 200 mg tablet once daily
2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily
2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily plus other HTN medications
|
Sperimentale: LCZ696 400 mg plus other hypertension (HTN) medications
All participants were started on LCZ696 200 mg once daily on day 1.
For participants who received LCZ696 400 mg and did not achieve msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4 and had no signs of safety concerns, another class of antihypertensive drugs (other than Angiotensin II receptor blockers or Angiotensin Converting Enzyme Inhibitor (ACEi) could be added, or the dose of concomitant antihypertensive drugs could be increased as per the package insert.
Participants who received LCZ696 400 mg once daily did not change their dose for the remainder of the study.
|
LCZ696 200 mg tablet once daily
2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily
2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily plus other HTN medications
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events and Deaths
Lasso di tempo: Week 8
|
Adverse events, serious adverse events deaths were monitored from screening to week 8.
|
Week 8
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change From Baseline in msSBP and msDBP at Week 8
Lasso di tempo: Baseline, 8 weeks
|
Sitting BP measurements were performed at screening through the end of study at every visit.
Four separate sitting BP measurements were obtained with a full two-minute interval between measurements.
The 4 measurements were summed and averaged, and then the baseline BP value was subtracted from the average value to get the change from baseline value.
|
Baseline, 8 weeks
|
Percentage of Participants With Successful Blood Pressure (BP) Control in msSBP/msDBP at End of Study
Lasso di tempo: 8 weeks
|
Successful BP control in patients with severe hypertension at the end of study treatment was defined as follows: msSBP/msDBP< 140/90 mmHg.
|
8 weeks
|
Percentage of Participants Achieving Successful msSBP Control at End of Study
Lasso di tempo: 8 weeks
|
Successful msSBP control in patients with severe hypertension at the end of study treatment was defined as msSBP <140 mmHg.
|
8 weeks
|
Percentage of Participants Achieving Successful msDBP Control at End of Study
Lasso di tempo: 8 weeks
|
Successful msDBP control in patients with severe hypertension at the end of study treatment was defined as msDBP < 90 mmHg.
|
8 weeks
|
Percentage of Participants With SBP Response at End of Study
Lasso di tempo: Baseline, 8 weeks
|
SBP response was defined as <140 mmHg or a reduction ≥ 20 mmHg from baseline.
|
Baseline, 8 weeks
|
Percentage of Participants With DBP Response at End of Study
Lasso di tempo: Baseline, 8 weeks
|
DBP response was defined as <90 mmHg or a reduction ≥ 10 mmHg from baseline.
|
Baseline, 8 weeks
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CLCZ696A1305
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Severe Hypertension
-
Acibadem UniversityCompletatoAndatura | Malattia di Sever | Apofisite calcanealeTacchino
-
University of Colorado, DenverCompletato
-
Fundacion PodoactivaCompletatoMalattia di Sever | Apofisite calcanealeSpagna
-
University of DelawareCompletatoMalattia di Sever | Tendinopatia d'Achille | Tendinopatia inserzionale dell'Achille | Apofisite; CalcaneoStati Uniti
-
Ann & Robert H Lurie Children's Hospital of ChicagoAmerican Medical Society for Sports MedicineSconosciutoSindrome di Osgood-Schlatter | Sinding-Larsen e sindrome di Johansson | Malattia di Sever | ApofisiteStati Uniti
Prove cliniche su LCZ696
-
Novartis PharmaceuticalsCompletatoInsufficienza cardiaca e frazione di eiezione ridottaStati Uniti
-
Novartis PharmaceuticalsCompletatoInsufficienza cardiaca cronica con frazione di eiezione ridottaBelgio, Estonia, Danimarca, Grecia, Regno Unito, Germania, Lettonia, Lituania, Spagna, Olanda, Bulgaria, Finlandia, Polonia, Cechia, Islanda, Svezia, Francia, Irlanda, Norvegia
-
Novartis PharmaceuticalsCompletatoInsufficienza cardiaca acutaStati Uniti
-
Novartis PharmaceuticalsCompletatoInsufficienza cardiaca cronica (CHF)Spagna, Croazia, Taiwan, Germania, Italia, Stati Uniti, Australia, Olanda, Svizzera, Belgio, Regno Unito, Bulgaria, Lituania, Federazione Russa, Francia, Argentina, Corea, Repubblica di, Polonia, Canada, Tacchino
-
Novartis PharmaceuticalsCompletatoIpertensioneStati Uniti, Spagna, Filippine, Guatemala, Federazione Russa, Argentina, Porto Rico
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletatoArresto cardiacoStati Uniti
-
University Hospital, MontpellierCompletatoInsufficienza cardiaca cronica | Sindrome delle apnee notturneFrancia
-
Novartis PharmaceuticalsCompletatoIpertensione essenzialeCina, Corea, Repubblica di, Taiwan, Hong Kong, Tailandia, Filippine, Singapore
-
AB FoundationCompletato
-
Novartis PharmaceuticalsCompletatoInsufficienza cardiaca con frazione di eiezione ridotta (HF-rEF)Giappone